FDA Panel Recommends Against Ampligen Approval

Last week's FDA Arthritis Advisory Committee meeting was the first time a panel convened to review a drug application for the treatment of CFS. Although most committee members found the data to reflect some interesting trends and a vote on safety went in favor of Ampligen, the final recommendation sent to the FDA was not to approve Ampligen for CFS. Compelling testimony from members of the public could not overcome the committee's need for more data to recommend that the IV drug is effective. Read more about the meeting, media coverage and what's next in the review process and for the drug at [http://bit.ly/FDA-panel-outcome](http://bit.ly/FDA-panel-outcome).

---

**EVERY GIFT COUNTS**

As one of our valued Research1st readers, thank you for your interest in CFS and the CFIDS Association's crucial efforts to end the life-altering disability, stigma and isolation CFS causes. We work every day toward a future free of CFS; your participation and financial support make that work possible. A [year-end gift](http://bit.ly/FDA-panel-outcome) will fuel new growth of vital research programs and will help us continue important support programs like [Research1st News](http://bit.ly/FDA-panel-outcome) that reaches thousands of readers every month with a digest of the latest research-focused
information. **Every gift matters** as we work together to make CFS history.

**UPCOMING EVENTS**

**Jan. 14, 2013:** The CDC will host a Patient-Centered Outreach and Communications Activity teleconference at 3:00 PM (EST). The topic of this meeting will be "redefining exercise in CFS through redefining aerobic activity" and the guest speaker will be Dr. Nancy Klimas. CDC staff will also provide updates on their research and outreach programs. To be added to the mailing list for further details, please send an email message to: CFSPCOCACall@cdc.gov

**Next spring** the FDA will sponsor a stakeholder meeting about clinical outcome measures in ME and CFS. We’ll share additional details as they become available. The FDA has archived information about drug development in ME/CFS here: http://1.usa.gov/NIzk2S
Our Mission:
For CFS to be widely understood, diagnosable, curable and preventable.

Our Strategy:
To stimulate research aimed at the early detection, objective diagnosis and effective treatment of CFS through expanded public, private and commercial investment.

Our Core Values:
To lead with integrity, innovation and purpose.